Alzamend Neuro Stock (NASDAQ:ALZN)


RevenueOwnershipFinancialsChart

Previous Close

$1.25

52W Range

$1.06 - $15.06

50D Avg

$1.44

200D Avg

$4.18

Market Cap

$6.03M

Avg Vol (3M)

$210.57K

Beta

-0.04

Div Yield

-

ALZN Company Profile


Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Jun 15, 2021

Website

ALZN Performance


ALZN Financial Summary


Apr 24Apr 23Apr 22
Revenue---
Operating Income$-9.94M$-14.87M$-12.32M
Net Income$-9.95M$-14.88M$-12.40M
EBITDA$-9.94M$-14.85M$-12.32M
Basic EPS$-14.70$-22.89$-20.92
Diluted EPS$-14.70$-22.89$-20.88

Fiscal year ends in Apr 24 | Currency in USD

Peer Comparison


TickerCompany
SNTISenti Biosciences, Inc.
DAWNDay One Biopharmaceuticals, Inc.
HOOKHOOKIPA Pharma Inc.
ALECAlector, Inc.
INZYInozyme Pharma, Inc.
XFORX4 Pharmaceuticals, Inc.
ADVMAdverum Biotechnologies, Inc.
ABOSAcumen Pharmaceuticals, Inc.
SLDBSolid Biosciences Inc.
KZRKezar Life Sciences, Inc.
TERNTerns Pharmaceuticals, Inc.
ADAGAdagene Inc.
MOLNMolecular Partners AG